Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation

Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation

IntroductionUpfront autologous stem cell transplantation (ASCT) has been recommended for patients who are newly diagnosed with peripheral T-cell lymphoma (PTCL), and CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), an anthracycline-based chemotherapy has been the frontline chemothe...

Full description

Bibliographic Details
Main Authors: Seok Jin Kim, Jae-Cheol Jo, Dok Hyun Yoon, Deok-Hwan Yang, Sang Eun Yoon, Gyeong-Won Lee, Jee Hyun Kong, Yong Park, Ka-Won Kang, Ho-Sup Lee, Sung Yong Oh, Ho-Jin Shin, Won Sik Lee, Yoon Seok Choi, Seong Hyun Jeong, Min Kyoung Kim, Hye Jin Kang, Jun Ho Yi, Sung-Nam Lim, Ho-Young Yhim, Young Rok Do, Hwan Jung Yun, Hyeon-Seok Eom, Mark Hong Lee, Cheolwon Suh, Won Seog Kim
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Oncology
Subjects:
T-cell
lymphoma
chemotherapy
autologous stem cell transplantation
progression-free survival
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1230629/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1230629/full

Similar Items